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Abstract
Background: Epigenetic changes associated with promoter DNA methylation results in silencing of several tumor
suppressor genes that lead to increased risk for tumor formation and for progression of the cancer.
Methods: Methylation specific PCR (MSP) and bisulfite sequencing were used for determination of proapoptotic
gene Caspase 8 (CASP8) and the tumor suppressor gene maspin promoter methylation in four breast cancer and
two non-tumorigenic breast cell lines. Involvement of histone H3 methylation in those cell lines were examined by
CHIP assay.
Results: The CpG sites in the promoter region of CASP8 and maspin were methylated in all four breast cancer cell
lines but not in two non-tumorigenic breast cell lines. Demethylation agent 5-aza-2’-deoxycytidine (5-aza-dc)
selectively inhibits DNA methyltransferases, DNMT3a and DNMT3b, and restored CASP8 and maspin gene
expression in breast cancer cells. 5-aza-dc also reduced histone H3k9me2 occupancy on CASP8 promoter in
SKBR3cells, but not in MCF-7 cells. Combination of histone deacetylase inhibitor Trichostatin A (TSA) and 5-aza-dc
significant decrease in nuclear expression of Di-methyl histone H3-Lys27 and slight increase in acetyl histone H3-
Lys9 in MCF-7 cells. CASP8 mRNA and protein level in MCF-7 cells were increased by the 5-aza-dc in combination
with TSA. Data from our study also demonstrated that treatment with 5-FU caused a significant increase in
unmethylated CASP8 and in CASP8 mRNA in all 3 cancer lines.
Conclusions: CASP8 and maspin expression were reduced in breast cancer cells due to promoter methylation.
Selective application of demethylating agents could offer novel therapeutic opportunities in breast cancer.
Background
Aberrant DNA methylation has been recognized as one
of the most common molecular alterations in human
neoplasia. Hypermethylation of gene-promoter regions
is being revealed as one of the most frequent event that
causes loss of gene function. DNA methylation usually
occurs at a cytosine associated with CpG sites [1]. DNA
(cytosine-5)-methyltransferase (DNA-MTase) catalyzes
this reaction by adding a methyl group from S-adeno-
syl-L-methionine to the fifth carbon position of the
cytosine [1]. Methylation of CpG sites in the promoter
region of the genes is known to transcriptionally repress
these genes [2]. CpG sites of a large number of genes
that are unmethylated in normal tissue are methylated
in human cancers, such as breast, ovarian, colon, and
prostate cancers [3,4]. Methylation at the promoter
region of specific genes depends on tumor type. For
example, the mismatch repair gene hMLH1 is silenced
by hypermethylation more frequently in colorectal,
endometrial, and gastric tumors; while the BRCA1 is
methylated in breast and ovarian tumors [5-8]. Recent
studies have suggested that CpG methylation of certain
genes may be associated with HER2 receptor overex-
pression and/or hormone status in breast cancer [8,9].
It is unclear as to which breast cancer specific genes are
transcriptionally silenced and if their silencing is asso-
ciated with failure in treatment and decrease in disease-
free survival (DFS).
CASP8 is an important initiator of apoptosis [10].
Absent or downregulation of CASP8 could cause
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able disease outcome, such as in childhood medulloblas-
toma and neuroblastoma [11,12]. The absence or
downregulation of CASP8 may be due to epigenetic
changes. Studies have also indicated that methylation
and demethylation of maspin promoter may regulate
maspin gene expression and that reduced maspin
expression is associated with cancer progression [13].
In the current study we used methylation specific PCR
(MSP), and bisulfite sequencing to determine the methy-
lation status of these two genes. We examined the
mechanisms associated with transcriptional silencing of
CASP8 and maspin by promoter methylation using real-
time PCR and by restoring the methylated genes back to
their unmethylated status using the demethylating agent,
5-aza-2’-deoxycytidine; TSA (Trichostatin A), inhibitor
of histone deacetylase; and chemotherapeutic agent 5-Fu
(5-Fluorouracil).
Methods
Cells and culture
The breast cancer cells with varying tissue subtypes
selected for our methylation studies were: MCF-7 (ER
positive and HER2/neu negative); MDA-MB231 (ER
negative and HER2/neu negative); SKBR3 (ER negative
and HER2/neu positive); HCC1937 (ER negative, HER2/
neu negative and BRCA1 mutated); non-tumorigenic
breast epithelial cells (MCF12A), and non-tumorigenic
breast fibroblast cells (MCF10). These cell lines were
purchased from American Type Culture Collection
(Rockville, MD), and unless otherwise stated, the cells
were grown and maintained in DMEM/F12 (Fisher
Scientific, CA) containing 10% FCS (Invetrogen), 2 mM
glutamine, 50 units/ml penicillin and 50 μg/ml strepto-
mycin (Fisher Scientific, CA).
5-aza-2’-deoxycytidine (5-aza-dc) and Trichostatin A (TSA)
treatment
The cells were growing in culture medium until 80%
confluence; 5 μM 5-aza-dc was added and incubated for
3 to 6 days. The medium containing 5-aza-dc was
refreshed every 2 days. For combination treatment cells
were first treated with 0.3 μM TSA in combination with
5 μM 5-aza-dc for 2 days and then TSA was removed
from culture medium. Treatment with 5 μM 5-aza-dc
was continued for 1 more day.
Bisulfite modification and Methylation Specific PCR (MSP)
Bisulfite conversion of genomic DNA was carried out
using Zymo EZ DNA Methylation-Gold™ kit (D5005,
Zymo Research Corp, Orange, CA) according to the
manufacture’s instructions. This process converts
unmethylated cytosine residues to uracil, while methy-
lated cytosine residues remain unchanged. Bisulfite
modified DNA was used as a template, and then MSP
was performed to determine the methylation status of
CASP8 and maspin. The primer sequences for MSP are
as follows:
(a) CASP8, 5’-TGTTGTTTGGGTAACGTATCGA-3’
(methylated forward),
5’-CCCTACTTAACTTAACCCTACTCGAC-3’
(methylated reverse), and
5’-TTGTTGTTTGGGTAATGTATTGA-3’
(unmethylated forward),
5’-CAACCCTACTTAACTTAACCCTACTCA-3’
(unmethylated reverse);
(b) maspin, 5’-ATTTTATCGAATATTTTATTTT
TCGG-3’ (methylated forward),
5’-TAACTCACCTAAACAACACCGCC-3’ (methy-
lated reverse), and
5’-TTTTATTTTATTGAATATTTTATTTTTTGG-
3’ (unmethylated forward),
5’-TAACTCACCTAAACAACACCACC-3’
(unmethylated reverse).
The primers for MSP were designed using MethPri-
mer [14] according to the sequences provided by
Panomics (Fremont, CA). The cover regions were
shown in Additional file 1, Figure S1. PCR conditions
were as follows: an initial denaturation at 95°C for 5
min was followed by 40 cycles at 94°C for 30 s, 50°C for
30 s, and 72°C for 45 s and a final extension at 72°C for
7 min.
Bisulfite sequencing for CASP8 promoter
Bisulfite modified DNA (described above) was amplified
by two primer sets. The primer sequences were as fol-
lows: P1-CASP8 (nt -744 to nt -466), 5’-GGTGG
TGGGTGTTTGTAGTTTTAGT-3’ (forward) and 5’-
CCATCCTTAACCATATTCTCCAATTTA-3’ (reverse);
P2-CASP8 (nt -486 to nt +51), 5’-TAGATTTTTTGTA
AGAAAGAATGGTAT-3’ (forward) and 5’-ACAAAA
AAACAAAATCTAATCTCC-3’ (reverse). PCR condi-
tions were as follows: an initial denaturation at 95°C for
5 min was followed by 40 cycles of 94°C for 30 s, 52°C
for 30 s, and 72°C for 45 s and a final extension at 72°C
for 7 min. The PCR products were purified with QIA-
quick PCR purification kit (#28104, QIAGEN), and then
sent to Retrogen Inc (San Diego, CA) for sequencing.
The primers for bisulfite sequencing were designed
using MethPrimer [14]. The sequence was used to
design the bisulfate sequence primers were as same as
the sequence used to design primers for MSP. The spe-
cific cover regions for each primer site have been
demonstrated in Additional file 1.
Quantitative real-time PCR (Q-PCR)
Total RNA from cultured cells was isolated by using
RNeasy micro kit (#74004, QIAGEN) according to the
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by reverse transcription (RT) with ThermoScript™ RT-
PCR system (Invitrogen) according to the manufacture’s
instructions. Q-PCR analysis was performed with iCycle
iQ real-time PCR detection system (Bio-Rad Lab, Her-
cules, CA) using SYBR Green Master Mix (#204143,
QIAGEN). The primers used were as follows: (a)
CASP8, 5’-CCAGAGACTCCAGGAAAAGAGA-3’ (for-
ward) and 5’-GATAGAGCATGACCCTGTAGGC-3’
(reverse). (b) maspin, 5’-AGATGGCCACTTTGAGAA-
CATT-3’ (forward) and 5’-GGTTTGGTGTCTG
TCTTGTTGA-3’ (reverse). (c) housekeeping control
gene, 18 s, 5’-GATCCATTGGAGGGCAAGTC-3’ (for-
ward) and 5’-TCCCAAGATCCAACTACGAG-3’
(reverse). Reactions were characterized during cycling
when amplification of the PCR product was first
detected (Ct). The target message and the housekeeping
gene, 18 s, in breast cancer and non-tumorigenic cell
lines, were quantified by measuring Ct. The relative level
of target messages in cells was normalized on the basis
of its 18 s content by taking the difference of threshold
cycles between target gene and 18 s. Using non-tumori-
genic breast cancer cells or untreated breast cancer cells
as reference, the level of CASP8 and maspin in each
sample was normalized with the corresponding refer-
ence by taking the difference between threshold cycles.
Final results were expressed as N-fold difference in tar-
get gene expression relative to the reference.
Immunobloting and Immunofluorescence (IF)
For immunoblot analysis cells were lysed in 1 × lysis
buffer (20 mM Tris pH 7.5; 150 mM NaCl; 1 mM
EDTA; 1 mM EGTA; 1% Triton X-100; 2.5 mM sodium
pyrophosphate; 1 mM b-glycerolphosphate; 1 mM
Na3VO4;1μg/ml leupeptin; 0.1 mM PMSF) and protein
concentration was measured using BCA dye (Pierce).
Total protein (50 μg) from cell lysates was resolved on
SDS-PAGE followed by transfer to nitrocellulose mem-
brane. The membranes were incubated with antibodies
specific against Dnmt1 (IMG-261A, IMGENEX), Dnmt2
(IMG-281, IMGENEX), Dnmt3a (IMG-268A, IMGE-
NEX), Dnmt3b (IMG-184A, IMGENEX), and caspase-8
(#9746, Cell Signaling) according to manufacturer’s
instruction. Detection of antigen-bound antibody was
performed with the enhance chemiluminescence
reagent. For immunofluorescence analysis cells (2 × 10
4/
each) were mounted by cytospin on polylysine coated
glass slides and fixed with 4% paraformaldehyde for 15
min followed by 100% ice-cold acetone for 10 min at 4°
C. To detect caspase-8 protein expression immunofluor-
escence analysis was performed with cleaved caspase-8
antibody (#9496, Cell Signaling) followed by incubation
with anti-goat IgG-FITC (Santa Cruz) for 30 min in
dark and mounted with DAPI mounting medium (Vec-
tor Labs). The cells with positive staining were counted
in five different areas and adjusted with total number of
cells. To analyze histone H3 methylation and acetylation
status in MCF-7 cells double immunofluorescence ana-
lysis was performed with antibodies against Di-Methyl
Histone H3 (Lys27) (#9755, Cell Signaling) or Acetyl
Histone H3 (Lys9) (#9671, Cell Signaling) followed by
b-actin antibody (A1975, Sigma-Aldrich). FITC-conju-
gated secondary antibodies were used to label Di-Methyl
Histone H3 (Lys27) and Acetyl Histone H3 (Lys9). The
b-actin was labeled with Tex-red-conjugated secondary
antibody. After mounting, the cells were viewed under a
fluorescence microscope.
CHIP assay
Cells were fixed with formaldehyde (1% final concentra-
tion) to cross-link protein to DNA at room temperature
for 10 min after treated with or without 5-aza-dc (5 μM,
3 days), and then incubated with glycine (0.125 M final
concentration) for 5 min to stop the cross-linking. Solu-
ble chromatin was prepared as described previously
[15]. The chromatin was then diluted 1:10 with dilution
buffer (0.01% SDS, 1.1% Triton X-100, 1.2 mM EDTA,
16.7 mM Tris-HCl, 167 mM NaCl and a protease inhi-
bitor cocktail set (CalBiochem)), and subjected to immu-
noprecipitation with anti-dimethylated histone H3 lysine
9 (H3K9me2) antibody (#9753, Cell signaling). Pre-
immune serum (Santa Cruz) was also used as a control.
The chromatin and antibodies were incubated overnight
at 4°C. Chromatin/antibody complexes were recovered
by adding 30 μl of protein A/G Plus-agarose beads
(Santa Cruz) and incubating at 4°C for 2 h. The beads
were sequentially washed for 10 min each in 1 ml of
low salt, high salt and LiCl immune complex wash buf-
fer. Immunocomplexes were eluted off the beads by
incubation with 300 μlo f1 %S D Sa n d5 0m M
NaHCO3. The eluent was incubated at 65°C for 5 h or
overnight to reverse the formaldehyde-induced protein-
DNA cross-links. The DNA was extracted with phenol
and chloroform. Extracted DNA was resuspended in 100
μl of TE buffer and real time PCR was performed by
using Bio-Rad thermal cycler with CASP8 primers: for-
ward 5’GGT GCC TGT AGT CCC AGC TAC TC3’
and reverse 5’CCT AGA CCC TCC CCT GTT CTG
TC3’. For input DNA, the chromatin preparation with-
out incubated with antibodies was subjected to real time
PCR.
Results
Promoter methylation on CASP8, and maspin resulted in
decrease mRNA and protein expression
First, we determined the promoter methylation status in
four breast cancer and one non-tumorigenic breast cell
l i n e sb yM S P .W et h e ne x a m i n e di ft h ep r o m o t e r
methylation would silence or decrease the gene or pro-
tein expression for CASP8 and maspin in different
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asked whether the 5-aza-cd treatment would reverse the
methylation and change the mRNA expression of these
genes. Results from MSP showed that CASP8 promoter
was methylated in breast cancer cells, MCF-7, MB231,
SKBR3, and HCC1937; but not in non-tumorigenic
breast cells, MCF-10 (Figure 1A). The CASP8 promoter
methylation resulted in the gene silence and lack of
CASP8 in those breast cancer cells. CASP8 mRNA level
were decreased significantly in all four breast cancer
cells compared to non-tumorigenic breast cells, MCF-10
(Figure 1B). All four breast cancer cell lines, MCF-7,
MB231, SKBR3 and HCC1937, lacked protein expres-
sion of caspase-8 (Figure 1C). Bisulfite sequence analysis
demonstrated the position of the methylated CpG sites
of CASP8 in different breast cancer cells (Figure 1D).
The mRNA level of maspin was decreased in MCF-7
cells; it was undetectable in MB231 and SKBR3 and
remained high level in HCC1937 compared to MCF10
cells (Figure 2A). Consistent with the mRNA expression,
results from MSP demonstrated that the maspin promo-
ter in MCF-7, MB231 and SKBR3 were methylated (Fig-
ure 2B).
Effect of 5-aza dc on DNA methylation
Next, we examined if the mRNA expression of CASP8,
and maspin could be restored by demethylating the tar-
get genes. We treated MCF-7, SKBR3, and MB231 with
5 μM 5-aza-dc for 3 days and performed RT-Q-PCR.
Figure 3A confirms that gene expression of CASP8 in
MB231, SKBR3, and HCC1937 cells can be restored
with 5-aza-dc treatment. The protein expression of
CASP8 in MB231, SKBR3, and HCC1937 was also
restored with 5-aza-dc treatment (Figure 3B). The gene
and protein expression of CASP8, however, were not
restored with 5-aza-dc treatment for 3 days in MCF-7
cells (Figure 3A and 3B).
Figure 1 CASP8 promoter methylation resulted in decreased mRNA and protein expression.( A) DNA from the indicated cell lines were
modified by bisulfite treatment, and MSP were performed with methylated and unmethylated CASP8 PCR primers as described in Methods. The
bands detected by methylated primer represented methylated CASP8 (M), and the bands detected by unmethylated primer represented
unmethylated CASP8 (UM). (B) RNA were isolated from cells and performed for RT and real-time PCR with CASP8. The relative level of CASP8
gene was normalized to 18 s mRNA as described in Methods. Each bar represented the mean of three independent amplifications with standard
deviation (SD). (C) Total protein was isolated from the indicated cells, and Western blot analysis was performed with antibodies specific for full
length caspase-8. b-actin was used as loading control. (D). Bisulfite modified DNA from the indicated cells were amplified with CASP8 primer
designed according to the bisulfite modified sequence of CpG sites in CASP8 promoter as described in Methods. The amplified PCR products
were purified and sequenced to confirm the location of methylated CpG sites. The dark dots represent location of methylated CpG sites in the
promoter, and open dots indicate unmethylated CpG sites.
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in breast cancer cells may be due to promoter methyla-
tion, we performed MSP, which detected methylation of
CpG sites of CASP8 in 5-aza-dc untreated breast cancer
cells, MCF-7, MB231, SKBR3, and HCC1937 but not in
MCF10 (Figure 3C). MSP also detected unmethylated
CASP8 in MB231, SKBR3, and HCC1937 untreated cells
(Figure 3C). However, as shown in Figure 3C, 5-aza-dc
treatment completely demethylated the CASP8 promo-
ter in MB231, SKBR3, and HCC1937 cells. In contrast,
after treatment with 5-aza-dc, MSP detected a weak
band of unmethylated CASP8 in MCF-7 cells. A good
amount of methylated CASP8 still remained methylated
after 5-aza-dc treatment in MCF-7 cells (top panel of
Figure 3C). To determine the optimal time for treatment
with 5-aza-dc to induce demethylation of CASP8 in
MCF-7, cells were treated with 5-aza-dc from 3 to 6
days. MSP and RT-Q-PCR were used to assess the
extent of demethylation. There were no significant
changes in CASP8 promoter methylation as well as in
mRNA expression after 3 days treatment (data not
shown). However, after four days of treatment with 5-
aza-dc, we did see some restoration of unmethylated
CASP8. The CASP8 mRNA expression also increased
further after four days of treatment.
Taken together, the results from MSP confirmed that
the loss of CASP8 gene and protein expression in these
breast cancer cells resulted from CASP8 promoter
methylation. Results also confirmed that CASP8 gene
and protein can be restored by demethylation in
selected breast cancer cells. Bisulfite sequencing analysis
further demonstrated the position of demethylation of
CASP8 related to restoring CASP8 gene and protein
levels in 5-aza-dc treated cells (Figure 3D).
5-aza-dc treatment also reactivated gene expression of
maspin in MCF-7, MB231, and SKBR3 (Figure 3E). MSP
confirmed that the reactivated maspin gene expression
with 5-aza-dc treatment was consistent with demethyla-
tion on maspin promoter (Figure 3F). The CpG sites on
maspin promoter in HCC1937 cells were not methy-
lated; hence, we did not perform RT-Q-PCR and MSP
for maspin on HCC1937 cell treated with 5-aza-dc. The
increased gene expression following demethylation sug-
gested that methylation-dependent transcriptional silen-
cing may cause decreased expression or even total loss
of CASP8 and maspin in breast cancer cells.
Effect of 5-aza-dc on DNA Methyltransferases
Since, 5-aza-dc (inhibitor of DNA methyltransferase)
treatment did not demethylate CASP8 promoter region,
we examined if 5-aza-dc was able to inhibit DNMTs
(DNA methyltransferases). Figure 4A shows that 5-aza-
dc treatment did not inhibit DNMT1, DNMT3a and
DNMT3b in MCF-7 cells. However, it did inhibit
DNMT3a and DNMT3b in MDAMB231 and BT474
(ER positive and HER2 positive) breast cancer cells. We
did not detect DNMT2 in any of the cell lines tested. In
Figure 2 Maspin promoter methylation resulted in decreased mRNA and protein expression.( A) RNA were isolated from cells and
performed for RT and real-time PCR with maspin primers. The relative level of the maspin gene was normalized to 18 s as described in
Methods. Each bar represented the mean of three independent amplifications with standard deviation (SD). (B) DNA from the indicated cell lines
were modified by bisulfite treatment, and MSP were performed with methylated and unmethylated maspin PCR primers as described in
Methods. The bands detected by methylated primer represented methylated maspin (M), and the bands detected by unmethylated primer
represented unmethylated maspin (UM).
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three breast cancer cells tested.
CHIP Assay to determine the specificity of CASP8
demethylation in response to 5-aza-dc
DNA methyltransferase inhibitors commonly used in
clinical trials promote tumor cell death, but their
detailed cytotoxic action is not yet fully understood. A
deeper knowledge about their apoptosis-inducing
mechanisms and their interaction with DNA methyl-
transferases (DNMTs) DNMT1, DNMT3a, and
DNMT3b might allow the design of more effective
drugs with lower cytotoxicity. 5-aza-deoxycytidine (5-
aza-dc), a potent inhibitor of DNMT1, is known to
induce demethylation and reactivation of silenced genes.
Our data suggest that 5-aza-dc treatment increases
CASP8 transcription in MB231, SKBR3 and BT474, but
Figure 3 Effect of 5-aza-dc treatment on mRNA, protein expression and promoter methylation of CASP8 and maspin. Cells were treated
with 5 μM 5-aza-dc for 3 days. (A) RNA were isolated from the treated and untreated cells and performed for RT-PCR with CASP8 primers. b-
actin was used as loading control. (B) Total protein was isolated after cells were treated or untreated with 5-aza-dc. Western blot analysis was
performed with antibodies specific for full length caspase-8, and b-actin was used as loading control. (C) DNA were isolated and modified by
bisulfite treatment. MSP was performed with methylated and unmethylated CASP8 PCR primers as described in Methods. The bands detected by
methylated primer represented methylated maspin (M), and the bands detected by unmethylated primer represented unmethylated maspin
(UM). (D) The DNA from 5-aza-dc treated and untreated cells were modified by bisulfite treatment and amplified with CASP8 primer designed
according to the bisulfite modified sequence of CpG sites in CASP8 promoter as described in Methods. The amplified PCR products were
purified and sequenced for confirmation the CpG sites methylation. The dark dots represented methylated CpG sites in the promoter, and open
dots indicated unmethylated CpG sites. (E) RNA from 5-aza-dc treated and untreated cells were used to perform RT and real-time PCR with
maspin primers. The relative level of maspin gene was normalized to 18 s as described in Methods. Each bar represented the mean of three
independent amplifications with standard deviation (SD). (F) DNA from cells treated and untreated with 5-aza-dc were modified by bisulfite
treatment, and MSP was performed with methylated and unmethylated maspin PCR primers as described in Methods. The bands detected by
methylated primer represented methylated maspin (M), and the bands detected by unmethylated primer represented unmethylated maspin
(UM).
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H3 lysine methylation represses gene transcription
[16,17]. Thus, we further investigated whether 5-aza-dc
reduces histone H3 methylation to activate CASP8 tran-
scription in breast cancer cells. Our results (Figure 4B)
show that 5-aza -dc inhibits H3K9me2 occupancy on
C A P S 8p r o m o t e ri nS K B R 3a n dM B 2 3 1 ,b u tn o ti n
MCF-7 cells lines. These results suggest that CASP8
gene transcription is restored in theses SKBR3 and
MB231, but not in MCF-7 cells.
Effect of inhibiting HDAC with TSA
Histone deacetylation is an important mechanism of
regulation of gene expression. Since MCF-7 cells treat-
ment with 5-aza-dc did not increase the levels of CASP8
gene and protein expression, we also investigated
whether treatment of MCF-7 cells with TSA (Trichosta-
tin A), inhibitor of histone deacetylase (HDAC), in
combination with 5-aza-dc could change the methyla-
tion status of CASP8 and alter the gene and protein
expression. As shown in Figure 5A, MCF-7 treated with
TSA (0.3 μM for 2 days) in combination with 5-aza-dc
partially demethylated CASP8 promoter. The mRNA
level of CASP8 was significantly increased (Figure 5B),
and the cleaved caspase-8 protein could be seen in cells
treated with TSA in combination with 5-aza expression
(Figure 5C). Consistent with the mRNA and protein
data, TSA in combination with 5-aza-dc treatment sig-
nificantly reduced Di-Methylated Histone H3 (Lys27)
and increased Acetylated Histone H3 (Lys9), as shown
in Figure 5D.
Effect of 5-Fu on CASP8
Recent studies have shown that the anticancer drug, 5-
fluorouracil (5-Fu), can upregulate CASP8 protein and
induce cell apoptosis in leukemia and breast cancer cells
Figure 4 Effect of 5-aza-dc on DNMTs, and H3K9me2.( A) Total protein from the 5-aza-dc treated and untreated cells was used to perform
Western blot analysis with antibodies specific against DNMT1, DNMT2, DNMT3a and DNMT3b as described in Methods. Antibody against b-actin
was also used as loading control. (B) Chromatins were extracted from cells with or without 5-aza-dc treatment as described in Methods.
Chromatin immunoprecipitation was performed with antibody specific against histone H3K9me2, and recovered DNA fragments were used for
Q-PCR with promoter specific primers of CASP8. Fold change of H3K9me2 occupancy was calculated based on the control (without 5-aza-dc
treatment). Each bar represented the mean of three independent amplifications with standard deviation (SD).
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breast cancer in clinical practice. We examined if 5-Fu
treatment could upregulate CASP8 in breast cancer and
if the upregulation involved demethylating CpG sites on
CASP8 promoter. As shown earlier, CASP8 mRNA was
undetectable in MCF-7 breast cancer cells due to pro-
moter methylation. We then treated MCF-7 cells with
5-Fu for 3 days and examined CASP8 mRNA levels. Fig-
ure 6A shows almost 4 fold increase in mRNA level in
MCF-7 cells treated with 5-Fu compared to non-treated
cells. The mRNA level of CASP8 in MB231 and SKBR3
treated with 5-Fu also increased 2.4 fold and 1.8 fold
respectively (Figure 6A). The increases in mRNA
expression are correlated with partial demethylation of
CpG sites on CASP8 promoter (Figure 6B). Bisulfite
sequencing confirmed the position (nt -642 to nt -532,
located in CASP8 core promoter region) of demethyla-
tion of CASP promoter by 5-Fu in these breast cancer
cells (Figure 6C).
Discussion
Hypermethylation of the promoter regions of various
genes has been recognized as one of the most frequent
mechanisms causing loss of gene function. The
Figure 5 Effect of TSA in combination with 5-aza-dc on CASP8.( A) DNA was isolated from the TSA and 5-aza-dc treated and untreated cells
and MSP was performed with methylated and unmethylated CASP8 PCR primers as described in Methods. The bands detected by methylated
primer represented methylated CASP8 (M), and the bands detected by unmethylated primer represented unmethylated CASP8 (UM). (B) RNA
was isolated from the TSA and 5-aza-dc treated and untreated cells. RT and Q-PCR was performed with CASP8 primers. The relative level of
CASP8 mRNA was normalized to 18 s as described in Methods. Each bar represented the mean of three independent amplifications with
standard deviation (SD), *p < 0.05 between indicated groups. (C) Immunofluorescence analysis was performed with cleaved caspase-8 antibody
followed by incubation with anti-goat IgG-FITC and mounted with DAPI mounting medium (left panel). The arrows indicate the FITC labeled
cleaved caspase-8 (green in the top panel of left), and the cell nucleus was labeled by DAPI (blue in bottom panel of left). The cells with positive
staining for cleaved caspase-8 were counted in five different areas and adjusted with total number of cells (right panel). Each bar represents the
mean of number of cells positive for cleaved caspase-8 in the five areas with standard deviation (SD), * p < 0.05 between the indicated groups.
(D) Double immunofluorescence analysis was performed with Di-Methyl Histone H3 (Lys27) or Acetyl Histone H3 (Lys9) antibodies followed by
actin antibody as described in Methods. The nucleus positive stained with Di-Methyl Histone H3 (Lys27) or Acetyl Histone H3 (Lys9) were labeled
with FITC as green (indicated by white arrows), and the cytoplasm stained with actin was labeled with Tex-red as red (indicated with light blue
arrows).
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cinogenesis has been demonstrated in several studies
[20-26]. However, the association between epigenetic
changes with cancer etiology needs to be elucidated.
Several cancer-related genes have been reported to be
silenced by aberrant methylation in breast cancer, such
as 14-3-3 s, E-cadherin and tissue inhibitor of metallo-
proteinase 3 (TIMP3) genes. Treatment with 5-aza-dc
activated the expression of 14-3-3 s [27] and E-cadherin
genes [28] in breast carcinoma cells and of TIMP3 in
different tumor cell lines [29,30].
Hypermethylation of CASP8 has been showed as a fre-
quent feature of relapsed glioblastoma compared with
the corresponding primary tumors [31]. The authors
suggested that epigenetic deregulation of the mitochon-
dria-independent apoptosis is a relevant characteristic in
recurrent glioblastoma. The development of targeted
therapies restoring functional extrinsic apoptosis, as
recently shown in vivo with the synergistic combination
of the DNA demethylating agent decitabine and TRAIL
[32], may provide a useful tool to overcome the
resistance of glioblastoma to contemporary treatment
modalities. Methylation of CASP8 gene has also been
reported in some childhood tumors and in neuroendo-
crine lung tumors [33]. CASP8 is an important initiator
of apoptosis [10]. Structurally, the promoter region of
CASP8 has binding sites for p53, nuclear factor-B (NF-
B), AP-1, SP-1, IRF-1, and Ets-like transcription factors
[34]. Therefore, CASP8 functions both as a pivotal
molecule for death-receptor-induced apoptosis and as a
selective signal transducer, such as for NF-B activation
[35]. Absent or downregulation of CASP8 could cause
resistance to apoptosis and is correlated with unfavor-
able disease outcome, such as in childhood medulloblas-
toma and neuroblastoma [11,12]. Others have also
demonstrated that absence or downregulation of CASP8
may be due to epigenetic changes, such as hypermethy-
lation, or mutations [36,37].
In current study we have investigated the promoter
methylation of CASP8 and maspin in relation to their
expression levels as well as the involvement of histone
methyltransferases and histone H3K9me2. Using MSP
Figure 6 Effect of 5-Fu on CASP8.( A) MCF-7, MB231, and SKBR3 cells were treated with or without 5-Fu (10 μM) for 3 days. RNA was isolated
from the treated and untreated cells and RT-real-time PCR was performed with CASP8 and 18 s primers. Each bar represented the mean relative
level of CASP8 and standard deviation (SD) from three measurements and normalized to 18 s. (B) DNA was isolated from the 5-Fu treated and
untreated cells and modified with bisulfite treatment. MSP was performed with methylated and unmethylated CASP8 primers. The bands
detected with methylated primer indicated methylated CASP8 (M), and the bands from unmethylated primer indicated unmethylated CASP8
(UM). (C) Bisulfite modified DNA from the indicated 5-Fu treated, and untreated cells were amplified with CASP8 primer designed according to
the bisulfite modified sequence of CpG sites in CASP8 promoter as described in Methods. The amplified PCR products were purified and
sequenced for confirmation of the CpG sites methylation. The dark dots in the bottom panel represented methylated CpG sites in the promoter,
and open dots indicated unmethylated CpG sites.
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relationship between aberrant cytosine methylation and
downregulated or loss of CASP8 in breast cancer cells.
We confirmed that CpG sites methylation in the promo-
ter region of CASP8 is the mechanistic basis for tran-
scriptional downregulation or silencing of CASP8 in
breast cancer cells. The methylation status of CASP8
can be completely or partially reversed by treatment
with 5-aza-dc in MB231, SKBR3, and BT474, but not in
MCF-7 breast cancer cells. The cells that had fewer
methylated CpG sites, such as MB231 and SKBR3 were
totally demethylated by 5-aza-dc. This change in
demethylation resulted in a significant increase in
CASP8 mRNA and protein expression. In contract
SKBR3 cells, most CpG sites of CASP8 were methylated
in MCF-7 cells. Results from MSP showed that methyla-
tion was partially reversed by 5-aza-dc in MCF-7 cells
a n dt h em R N Aa n dp r o t e i nl e v e lo fC A S P 8h a dn os i g -
nificant increase. We also examined the effect of histone
acetylation of CASP8 by treating MCF-7 cells with Tri-
chostatin A (TSA). The TSA treatment alone did not
change the methylation status and mRNA expression of
CASP8 in MCF-7 cells (data not shown). However, TSA
in combination with 5-aza-dc was able to partially
demethylate CASP8 promoter and increased CASP8
mRNA and protein expression in MCF-7 cells. The data
suggested the involvement of histone acetylation in the
regulation of CASP8 gene expression in MCF-7 cells.
CHIP analysis (Figure 4B) showed that 5-aza-dc treat-
ment inhibits H3K9me2 occupancy on CAPS8 promoter
in SKBR3 and MDA-MB231, but not in MCF-7 cells.
These results suggest that CASP8 gene transcription is
restored in theses SKBR3 and MB231, but not in MCF-
7 cells.
Several studies have demonstrated a link between
methylation and histone acetylation in which a family of
methyl-CpG-binding proteins is involved [38]. When
these proteins bind to a methylated promoter, they
recruit HDAC, and the interaction of these two epige-
netic events inhibits gene expression by interfering with
the function of transcription factors and the compaction
of the chromatin structure [39-41]. Inhibitors of these
epigenetic changes can lead to the reactivation of genes
that suppress tumorigenesis. In accord with this hypoth-
esis is the report on the synergistic interaction of 5-aza-
dc and the HDAC inhibitor, trichostatin A (TSA), in the
reactivation of tumor suppressor genes [42]. This same
drug combination was also reported to induce a syner-
gistic reactivation of the estrogen receptor-a in breast
carcinoma cells [43].
A recent study in prostate cancer cells indicated that
CASP8 plays a pathway specific role in inhibiting andro-
gen receptor signaling [44]. This evidence suggests that
CASP8 may have the role beyond its role as a cell death
protease and may play a role in hormonal receptor cell
signaling.
The anticancer drug, fluorouracil (5-Fu), has been
commonly used in clinical practice for first line treat-
ment of breast cancer for decades. Up to now, except
for interferon-g and azacytidine, the cytotoxic drugs, 5-
Fu and methotrexate, have been shown to upregulate
CASP8 and induce cell apoptosis in neuroblastoma,
medulloblastoma, Ewing sarcoma, glioblastoma, leuke-
mia, and breast cancer cells [18,19]. The mechanism by
which 5-Fu regulates CASP8 protein is more likely to
involve p53 [19]. However, studies from Zoli, et al. [18]
s u g g e s tt h a t5 - F ui nc o m b i n a t i o nw i t hd o x o r u b i c i na n d
paclitaxel regulates CASP8 and induces cell apoptosis by
a caspase-dependent mechanism independent of hormo-
nal, p53, bcl-2 or bax status in breast cancer cells [18].
These observations made us to suspect that 5-Fu
induced cell apoptosis may involve a demethylation pro-
cess. We then tested the expression CASP8 mRNA, as
well as its methylation status, in MCF-7, MB231 and
SKBR3 cells treated with 5-Fu for 3 days. Compared to
untreated cells, the cells treated with 5-Fu showed a sig-
nificant increase mRNA expression of CASP8 followed
by demethylation of its promoter region.
Taken together, our results confirm that expression of
CASP8 in breast cancer is epigenetically controlled and
the modification may vary in different types of breast
cancer cells.
Another gene promoter methylation has been studied
was maspin in current study. Maspin belongs to the ser-
pin family [45]. It acts as a tumor suppressor, increases
cell adhesion, induces apoptosis, and inhibits tumor
growth and metastasis [46-48].M a s p i ni sa l s oi n v o l v e d
in angiogenesis and mammary gland development [49].
The expression of maspin is epigenetically controlled by
methylation and/or histone acetylation. Studies have
also indicated that methylation and demethylation of
maspin promoter may regulate maspin gene expression
and that reduced maspin expression is associated with
cancer progression [13]. In our study, we have con-
firmed that the expression of maspin in breast cancer
cells is epigenetically controlled by methylation of the
CpG sites. The demethylation agent, 5-aza-dc, treatment
reversed maspin promoter methylation and increased
maspin gene expression in MCF-7, MB231, and SKBR3
cells. An early study from Domann FE et al. [50] also
reported that normal human mammary epithelial cells
expressed maspin mRNA and displayed a completely
non-methylated maspin gene promoter. In contrast,
most breast cancer cell lines had no detectable maspin
expression and those maspin-negative breast cancer cell
lines also displayed an aberrant pattern of cytosine
methylation of the maspin promoter. In this study we
have also examined maspin and CASP8 mRNA levels in
Wu et al. BMC Cancer 2010, 10:32
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sues. The mRNA levels of CASP8 and maspin were
lower in breast cancer tissue than non-breast cancer tis-
sue (data not shown). The decreased mRNA expressing
levels of maspin and CASP8 in patients were associated
with positive lymph node status, late stage disease, and
HER2 overexpression (3+ and/or FISH positive). The
DFS was significant decreased in patients with low
CASP8 or maspin expression (data not shown). Inactiva-
tion of apoptotic pathways is often critical for the patho-
g e n e s i so ft u m o rc e l l sa n dfor their resistance to
chemotherapeutic drug treatment and/or irradiation
[51-53]. It needs to be determined if the loss of CASP8
and/or maspin expression can be a prognostic marker
for Breast Cancer and if it is associated with amplifica-
tion of MYCN (v-myc myelocytomatosis viral related
oncogene), as frequently observed in neuroblastomas.
Limitations of this study are that the most investiga-
tion was used cell lines only. To better understand the
clinical relevance of CASP8 and/or maspin promoter
methylation in breast tumors and if the decreased
mRNA expression of CASP8 and/or maspin were corre-
lated to the aberrant pattern of cytosine methylation of
the gene promoter further studies with large sample size
should be conducted.
Conclusions
In conclusion, our results show that methylation of CpG
sites at the promoter region in certain genes, such as
CASP8 and maspin, could result in transcriptional
downregulation or silencing of genes and protein in
breast cancer cells. The anticancer drug, 5-Fu, is able to
upregulate CASP8 gene expression, and the mechanism
may involve demethylation. Screening promoter methy-
lation patterns in breast cancer patients could be an
important step to develop treatment protocols that tar-
get the methylated gene and improve DFS in breast can-
cer patients. Future studies also should examine the use
of non-toxic demthylating agents in combination with
chemotherapeutic drugs would offer an advantage for
the treatment of breast cancer patients.
Additional file 1: Figure S1. Promoter CpG sites of CASP8 and
maspin and the primers sequences covered regions. A figure to
show the primers sequences used for MSP and bisulfate sequence
covered regions in CASP8 promoter. Figure Legend for Figure S1.
Click here for file
[http://www.biomedcentral.com/content/supplementary/1471-2407-10-
32-S1.PPT]
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